Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
9+ hour, 15+ min ago (848+ words) Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). In the primary endpoint analysis, Enhertu monotherapy significantly reduced…...
Enhertu Shows 14.3-Month PFS in HER2+ Lung Cancer Trial
7+ hour, 30+ min ago (338+ words) Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (#WCLC26) hosted by the International Association for the Study of Lung Cancer in Seoul, South Korea (abstract #PL03.08). In the primary endpoint of PFS, Enhertu monotherapy…...
Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit
7+ hour, 44+ min ago (41+ words) marketscreener.com Otsuka Holdings Co., Ltd. Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit Published on 09/14/2026 at 01:08 am EDT...
Cast Your Votes for Jobson's 2026 EyeVote Readers' Choice Awards, Nominations Close September 28
8+ hour, 37+ min ago (400+ words) NEWARK, N.J.—Vision Monday and 20/20 magazine are hosting the 18th annual EyeVote Readers' Choice Awards to identify the optical industry’s favorite products and companies this year. These two Jobson Medical Information publications are teaming up once again to get readers’ opinions by…...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
9+ hour, 15+ min ago (1000+ words) AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on…...
Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List
10+ hour, 6+ min ago (69+ words) marketscreener.com Every day, we give you free access to essential global business and financial news, through the work of our journalists and our partnerships with leading news and data providers. Jiangsu Hengrui Pharmaceuticals Co.,Ltd Hengrui Pharmaceuticals' Lung Cancer…...
FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug
10+ hour, 24+ min ago (124+ words) PharmaDispatch FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug Telix Pharmaceuticals has secured landmark approval from the United States Food and Drug Administration for Pixclara, making it the first FDA-sanctioned imaging agent for glioma, the…...
Huinno passes technology assessment for Kosdaq special listing
10+ hour, 57+ min ago (330+ words) Huinno, a digital healthcare company specializing in AI-powered cardiac monitoring, has passed the technology assessment required for a technology-based special listing on Kosdaq, moving a step closer to an initial public offering. Intermittent arrhythmias can be difficult to detect through…...
Phase III MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for Small-Cell Lung Cancer
23+ hour, 58+ min ago (171+ words) Sep 13, 2026, 08:54 ET For decades, PCI has been used after initial therapy for SCLC because studies conducted before routine MRI demonstrated that it reduced brain metastases and improved overall survival. MAVERICK was designed to determine whether modern MRI surveillance could allow…...
Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China. [IMAGE] | EurekAlert! Science News Releases
1+ day, 7+ hour ago (74+ words) dijo la profesora Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China. EurekAlert! Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer…...